1-甲基-4-[2-(4-甲基-3,5-二氧代哌嗪-1-基)乙基]哌嗪-2,6-二酮 | 1155-54-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1-甲基-4-[2-(4-甲基-3,5-二氧代哌嗪-1-基)乙基]哌嗪-2,6-二酮
• 中文别名: 左旋丙亚胺158；4,4'-(1,2-乙基)二[N-甲基-2,6-哌嗪二酮]
• 英文名称: ICRF-158
• 英文别名: 1,1'-dimethyl-4,4'-ethane-1,2-diyl-bis-piperazine-2,6-dione；4,4'-Ethylenebis(1-methyl-2,6-piperazinedione)；1-methyl-4-[2-(4-methyl-3,5-dioxopiperazin-1-yl)ethyl]piperazine-2,6-dione
• CAS: 1155-54-0
• 化学式: C₁₂H₁₈N₄O₄
• 分子量: 282.299
• InChiKey: OPWGVQGWPKYWOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  81.2
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  1-甲基-4-[2-(4-甲基-3,5-二氧代哌嗪-1-基)乙基]哌嗪-2,6-二酮 、 copper(II) acetate 以72%的产率得到
  参考文献：
  名称：

  HOUGHTON, R. P.;WILLIAMS, E., J. CHEM. SOC. PERKIN TRANS., 1982, N 11, 2693-2696

  摘要：

  DOI：
• 作为产物：
  描述：

  1,3-二甲基脲 生成 1-甲基-4-[2-(4-甲基-3,5-二氧代哌嗪-1-基)乙基]哌嗪-2,6-二酮
  参考文献：
  名称：

  CAPEK, KAREL;CAPKOVA, JINDRA;JARY, JIRI

  摘要：

  DOI：

文献信息

• CAPEK, KAREL;CAPKOVA, JINDRA;JARY, JIRI
  作者：CAPEK, KAREL、CAPKOVA, JINDRA、JARY, JIRI

  DOI：——

  日期：——
• A METHOD OF REDUCING AMYLOID-BETA PEPTIDE LEVELS USING A BISDIOXOPIPERAZINE
  申请人：The Govt Of The USA, As Represented By The Secretary, Department Of Health And Human Services

  公开号：EP2035003A1

  公开（公告）日：2009-03-18
• Method of reducing amyloid-beta peptide levels using a bisdioxopiperazine
  申请人：Greig Nigel H.

  公开号：US20100144704A1

  公开（公告）日：2010-06-10

  Disclosed are methods of reducing amyloid-β peptide levels in a subject. The method involves administering to the subject a therapeutically effective amount of a bisdioxopiperazine or a pharmaceutically acceptable salt thereof to reduce β-amyloid peptide levels.
• NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA
  申请人：University of Florida Research Foundation, Inc.

  公开号：US20130281389A1

  公开（公告）日：2013-10-24

  Topoisomerase II alpha (topo IIα) is exported from the cell nucleus in human myeloma cells by a chromosome-maintenance protein-1 (CRM1)-dependent mechanism, resulting in topo II inhibitor resistance. The nuclear export signal (NES) of topo IIα is unique, making it a potential target for small molecule inhibitors. Small molecules NES inhibitors were identified, which inhibited binding of topo IIα to the export receptor CRM1. Inhibition was specific to topo IIα as p53 trafficking was unaffected along with topo IIα protein expression and function (decatenation). These topo IIα-specific nuclear export inhibitors may potentially lead to a new approach in circumventing drug resistance in multiple myeloma. The compounds provide a protocol for treating multiple myeloma or an oncogenic disease. Further, the topoisomerase II nuclear export signal inhibitor may be combined with a topoisomerase II inhibitor.
• US5421897A
  申请人：——

  公开号：US5421897A

  公开（公告）日：1995-06-06